A retrospective study suggested Vistide significantly improved the lives of 70% of severely ill ME/XCFS patients.
In a first for ME/CFS, at the HHV6 Conference in Paris Dr. Peterson reported a retrospective study indicated a little used anti-herpesvirus drug called Vistide significantly helped 70% of severely ill patients – with many able to return to work. With this unusually high success rate in this difficult to treat group Peterson called for multi-center studies to build on these results.
Click here to read the blog on the Simmaron Foundation website
Wow – thanks Cort – your own researches are what you might say on a roll now.
I really hope a clinical trial and paper is followed up with this.This is something that can prove to the FDA, for a subset of patients with Severe ME, that this drug could make a difference. I know the only down fall is it’s infused over a long time but what about Valcyte it’s sister drug? This can open the door to hard hitting anti-virals .